

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

**VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE
INSPECTION BY LANGHUA PHARMACEUTICAL,
A WHOLLY-OWNED SUBSIDIARY**

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Zhejiang Langhua Pharmaceutical Co., Ltd. (“**Langhua Pharmaceutical**”), a wholly-owned subsidiary of Viva Biotech Holdings (the “**Company**”), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration (“**FDA**”) in the second half of 2024, which covered six major systems, namely, quality system, materials, production, packaging and labeling system, equipment and facilities, and laboratory control. The Company has recently been informed that Langhua Pharmaceutical received the EIR (Establishment Inspection Report) from the U.S. FDA. In accordance with the 21 CFR (Code of Federal Regulations Title 21), the FDA confirmed that the inspection had been completed and that Langhua Pharmaceutical had passed the cGMP on-site inspection conducted by the FDA.

This is the fourth time that Langhua Pharmaceutical has undergone and passed the on-site inspection by the FDA, indicating the continuous compliance with FDA’s cGMP standards in terms of the quality control system and production environment and facilities of the Company. This reaffirms the effective operation of the Company’s quality control system, provides solid support for the Company’s continuous expansion into the international market, and facilitates the Company in offering global customized research, development and production services to pharmaceutical enterprises worldwide, thereby contributing positively to enhancing the Company’s overall competitiveness and future development.

Due to the characteristics of the pharmaceutical industry, the production and sales of pharmaceutical products are subject to certain uncertainties arising from the market environment, industry policies, supply and demand, and other factors. Investors are advised to exercise caution and be aware of the risks involved.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, March 27, 2025

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; two Non-executive Directors, namely, Mr. Wu Yuting and Mr. Wang Stephen Hui; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.